The company focuses on the discovery and development of pro-drug cancer therapeutics that are converted into active drugs at the tumor site. Their current development candidates include G-202, which is in Phase I clinical trials and targets the blood vessels of solid tumors, and G-114, G-115, and Ac-GKAFRR-L12ADT, which are in pre-clinical animal models for prostate cancer treatment. Founded in 2003 and based in San Antonio, Texas, Inspyr Therapeutics is a clinical-stage oncology company specializing in novel precision therapeutics for cancer treatment.